Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Universitaire Ziekenhuizen Leuven |
---|---|
Information provided by: | Universitaire Ziekenhuizen Leuven |
ClinicalTrials.gov Identifier: | NCT00452049 |
Secondary hyperparathyroidism (HPT) is a known complication of chronic renal failure. Elevated concentrations of parathyroid hormone (PTH) play a role not only in the pathogenesis of renal bone disease, but also in the development of cardiovascular risk factors such as disturbed lipid metabolism, glucose intolerance, and hypertension. HPT is also known to play an important role in the development of structural abnormalities of both large arteries and the heart (left ventricular hypertrophy, interstitial fibrosis). In the last couple of years there has been increasing evidence from animal studies that the endothelium is a target organ of PTH.
Hypothesis: PTH has clinically relevant effects on renal hemodynamics, renal function and endothelial function.
Aims:
Condition | Intervention |
---|---|
Hyperparathyroidism Hypertension |
Procedure: parathyroidectomy |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Observational Study to Evaluate the Effect of Parathyroidectomy on Renal Function, Endothelial Function and Blood Pressure |
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Renal transplant recipients
Inclusion Criteria:
Contact: Pieter Evenepoel, MD, PhD | 003216344580 | pieter.evenepoel@uz.kuleuven.ac.be |
Belgium | |
University Hopsital Leuven | Recruiting |
Leuven, Belgium, 3000 | |
Contact: Pieter Evenepoel, MD, PhD 003216344580 pieter.evenepoel@uz.kuleuven.ac.be |
Principal Investigator: | Pieter Evenepoel, MD, PhD | University Hospital Leuven |
Responsible Party: | University Hospitals leuven ( Prof Vanrenterghem ) |
Study ID Numbers: | ML3052 |
Study First Received: | March 23, 2007 |
Last Updated: | March 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00452049 History of Changes |
Health Authority: | Belgium: Directorate general for the protection of Public health: Medicines |
parathyroidectomy arterial stiffness renal function |
Parathyroid Diseases Hyperparathyroidism Vascular Diseases |
Endocrine System Diseases Endocrinopathy Hypertension |
Parathyroid Diseases Hyperparathyroidism Vascular Diseases |
Endocrine System Diseases Cardiovascular Diseases Hypertension |